SMT202500400T1 - Trattamento della dmle usando una variante di aav2 con aflibercept - Google Patents

Trattamento della dmle usando una variante di aav2 con aflibercept

Info

Publication number: SMT202500400T1
Authority: SM; San Marino
Prior art keywords: aflibercept; amd; treatment; aav2 variant; aav2
Prior art date: 2016-06-16

Application number

SM20250400T

Other languages

English (en)

Inventor

Mehdi Gasmi

Mark Blumenkranz

Original Assignee

Adverum Biotechnologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-16

Filing date

2017-06-16

Publication date

2025-11-10

2017-06-16 Application filed by Adverum Biotechnologies Inc filed Critical Adverum Biotechnologies Inc

2025-11-10 Publication of SMT202500400T1 publication Critical patent/SMT202500400T1/it

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Ophthalmology & Optometry (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Dispersion Chemistry (AREA)
Hematology (AREA)

SM20250400T 2016-06-16 2017-06-16 Trattamento della dmle usando una variante di aav2 con aflibercept SMT202500400T1 (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662351234P	2016-06-16	2016-06-16
EP20196657.9A EP3795181B1 (en)	2016-06-16	2017-06-16	Treatment of amd using aav2 variant with aflibercept

Publications (1)

Publication Number	Publication Date
SMT202500400T1 true SMT202500400T1 (it)	2025-11-10

Family

ID=60663653

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SM20250400T SMT202500400T1 (it)	2016-06-16	2017-06-16	Trattamento della dmle usando una variante di aav2 con aflibercept
SM20210010T SMT202100010T1 (it)	2016-06-16	2017-06-16	Trattamento della amd usando una variante aav2 con aflibercept

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SM20210010T SMT202100010T1 (it)	2016-06-16	2017-06-16	Trattamento della amd usando una variante aav2 con aflibercept

Country Status (25)

Country	Link
US (2)	US20190151409A1 (it)
EP (3)	EP3471780B1 (it)
JP (5)	JP6814822B2 (it)
KR (2)	KR102218265B1 (it)
CN (2)	CN109641065A (it)
AU (3)	AU2017286673B2 (it)
BR (1)	BR112018076124A2 (it)
CA (1)	CA3027737A1 (it)
CY (1)	CY1123697T1 (it)
DK (2)	DK3471780T3 (it)
ES (2)	ES2840059T3 (it)
FI (1)	FI3795181T3 (it)
HR (2)	HRP20251248T1 (it)
HU (1)	HUE051953T2 (it)
IL (3)	IL279919B2 (it)
LT (2)	LT3471780T (it)
MX (2)	MX391779B (it)
PL (1)	PL3795181T3 (it)
PT (2)	PT3471780T (it)
RS (2)	RS67328B1 (it)
SG (1)	SG11201811232XA (it)
SI (2)	SI3471780T1 (it)
SM (2)	SMT202500400T1 (it)
WO (1)	WO2017218974A2 (it)
ZA (1)	ZA201808538B (it)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3800191B1 (en)	2014-03-17	2025-08-20	Adverum Biotechnologies, Inc.	Compositions and methods for enhanced gene expression in cone cells
US11021519B2 (en)	2015-03-02	2021-06-01	Adverum Biotechnologies, Inc.	Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
ES2840059T3 (es) *	2016-06-16	2021-07-06	Adverum Biotechnologies Inc	Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept
CA3040179A1 (en)	2016-10-19	2018-04-26	Adverum Biotechnologies, Inc.	Modified aav capsids and uses thereof
EP4653536A3 (en)	2017-03-17	2026-02-25	Adverum Biotechnologies, Inc.	Compositions and methods for enhanced gene expression
CN107661492A (zh) *	2017-08-31	2018-02-06	中山大学中山眼科中心	Vegf‑b的新用途
CN107537026A (zh) *	2017-08-31	2018-01-05	中山大学中山眼科中心	Vegf‑b的应用
AU2018350990A1 (en) *	2017-10-18	2020-05-21	Regenxbio Inc.	Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
CN111770999A (zh) *	2017-11-27	2020-10-13	4D分子治疗有限公司	腺相关病毒变体衣壳和用于抑制血管生成的应用
EP3727468A4 (en)	2017-12-19	2021-09-22	Akouos, Inc.	AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
US20210154270A1 (en) *	2018-04-12	2021-05-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Anti-aging compositions and methods of use
DK4364724T3 (da)	2018-05-10	2025-12-22	Regeneron Pharma	Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
JP7597380B2 (ja) *	2019-03-04	2024-12-10	アドヴェラムバイオテクノロジーズ，インコーポレイテッド	対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
WO2020219868A1 (en) *	2019-04-24	2020-10-29	Regenxbio Inc.	Fully-human post-translationally modified antibody therapeutics
EP3886946A1 (en)	2019-06-05	2021-10-06	Regeneron Pharmaceuticals, Inc.	Devices and methods for precision dose delivery
HRP20260137T1 (hr) *	2019-09-11	2026-03-13	Adverum Biotechnologies, Inc.	Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept
CA3147843A1 (en) *	2019-09-11	2021-03-18	Mehdi Gasmi	Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
TWI819268B (zh)	2020-01-16	2023-10-21	詹姆斯Ｗ希爾	藉由基因轉導改變眼睛顏色
FR3111913A1 (fr) *	2020-06-30	2021-12-31	Eyevensys	Construction d’adn pour le traitement de pathologies oculaires
JP7842082B2 (ja) *	2020-07-21	2026-04-07	エフティージェンコーポレーション	眼疾患を処置するための組成物および方法
CN113952474A (zh) *	2020-07-21	2022-01-21	英斯培瑞有限公司	用于治疗眼部疾病的组合物和方法
CN113952473A (zh) *	2020-07-21	2022-01-21	英斯培瑞有限公司	用于治疗眼部疾病的组合物和方法
CN113817775B (zh) *	2020-08-25	2023-02-17	南京吉迈生物技术有限公司	修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
CA3192736A1 (en) *	2020-09-03	2022-03-10	University Of Massachusetts	Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
IL303317A (en)	2020-12-01	2023-07-01	Akouos Inc	ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2021049374A (ja) *	2020-12-09	2021-04-01	株式会社三洋物産	遊技機
BR112023019056A2 (pt) *	2021-04-27	2024-01-16	Adverum Biotechnologies Inc	Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte
AU2023220237A1 (en)	2022-02-21	2024-08-15	Shanghai Regenelead Therapies Co., Ltd	Vegf-binding molecule and pharmaceutical use thereof
USD1120314S1 (en)	2022-11-30	2026-03-24	Regeneron Pharmaceuticals, Inc.	Dose delivery device
TW202508610A (zh)	2023-08-23	2025-03-01	大陸商上海瑞宏迪醫藥有限公司	醫藥組成物及其用途
WO2025072688A2 (en) *	2023-09-27	2025-04-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
WO2025073297A1 (zh) *	2023-10-06	2025-04-10	甘李药业股份有限公司	表达抗vegf融合蛋白的aav病毒载体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105755044A (zh) *	2011-04-22	2016-07-13	加利福尼亚大学董事会	具有变异衣壳的腺相关病毒病毒体及其使用方法
ES2753135T3 (es) *	2012-05-07	2020-04-07	Allergan Inc	Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
TWI698240B (zh) *	2012-05-15	2020-07-11	澳大利亞商艾佛蘭屈澳洲私營有限公司	使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2013188316A1 (en) *	2012-06-11	2013-12-19	Avalanche Biotechnologies, Inc.	Optical regulation of gene expression in the retina
DK4374873T3 (da) *	2013-07-12	2025-11-03	Astellas Us Llc	Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
CA2926853C (en) *	2013-10-18	2022-04-26	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
US11021519B2 (en) *	2015-03-02	2021-06-01	Adverum Biotechnologies, Inc.	Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
ES2840059T3 (es) *	2016-06-16	2021-07-06	Adverum Biotechnologies Inc	Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept

2017
- 2017-06-16 ES ES17814223T patent/ES2840059T3/es active Active
- 2017-06-16 JP JP2018565845A patent/JP6814822B2/ja active Active
- 2017-06-16 BR BR112018076124A patent/BR112018076124A2/pt unknown
- 2017-06-16 PT PT178142238T patent/PT3471780T/pt unknown
- 2017-06-16 SM SM20250400T patent/SMT202500400T1/it unknown
- 2017-06-16 AU AU2017286673A patent/AU2017286673B2/en active Active
- 2017-06-16 DK DK17814223.8T patent/DK3471780T3/da active
- 2017-06-16 SG SG11201811232XA patent/SG11201811232XA/en unknown
- 2017-06-16 FI FIEP20196657.9T patent/FI3795181T3/fi active
- 2017-06-16 LT LTEP17814223.8T patent/LT3471780T/lt unknown
- 2017-06-16 EP EP17814223.8A patent/EP3471780B1/en active Active
- 2017-06-16 CN CN201780050283.2A patent/CN109641065A/zh active Pending
- 2017-06-16 PT PT201966579T patent/PT3795181T/pt unknown
- 2017-06-16 SM SM20210010T patent/SMT202100010T1/it unknown
- 2017-06-16 DK DK20196657.9T patent/DK3795181T3/da active
- 2017-06-16 IL IL279919A patent/IL279919B2/en unknown
- 2017-06-16 RS RS20251055A patent/RS67328B1/sr unknown
- 2017-06-16 HR HRP20251248TT patent/HRP20251248T1/hr unknown
- 2017-06-16 SI SI201730553T patent/SI3471780T1/sl unknown
- 2017-06-16 WO PCT/US2017/038003 patent/WO2017218974A2/en not_active Ceased
- 2017-06-16 IL IL314568A patent/IL314568B2/en unknown
- 2017-06-16 KR KR1020197001023A patent/KR102218265B1/ko active Active
- 2017-06-16 HR HRP20201842TT patent/HRP20201842T1/hr unknown
- 2017-06-16 EP EP20196657.9A patent/EP3795181B1/en active Active
- 2017-06-16 CN CN202311530329.4A patent/CN117531025A/zh active Pending
- 2017-06-16 MX MX2018015512A patent/MX391779B/es unknown
- 2017-06-16 CA CA3027737A patent/CA3027737A1/en active Pending
- 2017-06-16 HU HUE17814223A patent/HUE051953T2/hu unknown
- 2017-06-16 KR KR1020217004488A patent/KR20210021113A/ko not_active Ceased
- 2017-06-16 LT LTEP20196657.9T patent/LT3795181T/lt unknown
- 2017-06-16 PL PL20196657.9T patent/PL3795181T3/pl unknown
- 2017-06-16 EP EP25187377.4A patent/EP4671369A3/en active Pending
- 2017-06-16 RS RS20201517A patent/RS61311B1/sr unknown
- 2017-06-16 ES ES20196657T patent/ES3049818T3/es active Active
- 2017-06-16 SI SI201731629T patent/SI3795181T1/sl unknown
2018
- 2018-12-12 US US16/218,353 patent/US20190151409A1/en not_active Abandoned
- 2018-12-13 IL IL263686A patent/IL263686B/en active IP Right Grant
- 2018-12-13 MX MX2022004786A patent/MX2022004786A/es unknown
- 2018-12-18 ZA ZA2018/08538A patent/ZA201808538B/en unknown
2020
- 2020-09-16 JP JP2020155475A patent/JP2020203941A/ja not_active Withdrawn
- 2020-11-30 CY CY20201101133T patent/CY1123697T1/el unknown
2021
- 2021-09-01 AU AU2021225178A patent/AU2021225178B2/en active Active
- 2021-09-20 US US17/479,968 patent/US20220265740A1/en active Pending
2022
- 2022-07-15 JP JP2022113865A patent/JP2022137244A/ja active Pending
2024
- 2024-06-12 JP JP2024095160A patent/JP2024113193A/ja active Pending
2025
- 2025-04-28 AU AU2025202930A patent/AU2025202930A1/en active Pending
- 2025-09-12 JP JP2025152535A patent/JP2025186377A/ja active Pending

Also Published As

Publication number	Publication date
CN117531025A (zh)	2024-02-09
EP3795181A1 (en)	2021-03-24
AU2021225178A1 (en)	2021-09-30
IL314568A (en)	2024-09-01
AU2021225178B2 (en)	2025-01-30
IL263686B (en)	2021-02-28
PT3795181T (pt)	2025-11-05
DK3795181T3 (da)	2025-10-13
DK3471780T3 (da)	2020-11-23
JP2022137244A (ja)	2022-09-21
PT3471780T (pt)	2020-12-17
IL279919B2 (en)	2025-01-01
ES2840059T3 (es)	2021-07-06
IL314568B1 (en)	2025-05-01
JP2020203941A (ja)	2020-12-24
US20190151409A1 (en)	2019-05-23
HUE051953T2 (hu)	2021-04-28
BR112018076124A2 (pt)	2019-03-26
EP3471780A2 (en)	2019-04-24
EP3471780A4 (en)	2019-04-24
MX2018015512A (es)	2019-04-24
CY1123697T1 (el)	2022-03-24
IL263686A (en)	2019-01-31
IL279919A (en)	2021-03-01
KR20190037228A (ko)	2019-04-05
CN109641065A (zh)	2019-04-16
FI3795181T3 (fi)	2025-10-14
SI3795181T1 (sl)	2025-11-28
KR20210021113A (ko)	2021-02-24
WO2017218974A3 (en)	2018-01-25
EP4671369A3 (en)	2026-03-18
JP2025186377A (ja)	2025-12-23
LT3471780T (lt)	2021-01-25
SMT202100010T1 (it)	2021-03-15
ES3049818T3 (en)	2025-12-18
AU2017286673B2 (en)	2021-06-24
WO2017218974A2 (en)	2017-12-21
EP4671369A2 (en)	2025-12-31
SI3471780T1 (sl)	2021-03-31
ZA201808538B (en)	2021-04-28
IL279919B1 (en)	2024-09-01
HRP20251248T1 (hr)	2026-01-16
JP6814822B2 (ja)	2021-01-20
EP3795181B1 (en)	2025-08-06
IL314568B2 (en)	2025-09-01
JP2024113193A (ja)	2024-08-21
JP2019521990A (ja)	2019-08-08
AU2025202930A1 (en)	2025-05-15
US20220265740A1 (en)	2022-08-25
MX2022004786A (es)	2022-05-16
CA3027737A1 (en)	2017-12-21
RS67328B1 (sr)	2025-11-28
MX391779B (es)	2025-03-21
RS61311B1 (sr)	2021-02-26
HRP20201842T1 (hr)	2021-04-16
SG11201811232XA (en)	2019-01-30
AU2017286673A1 (en)	2019-01-31
LT3795181T (lt)	2025-12-29
PL3795181T3 (pl)	2025-12-22
KR102218265B1 (ko)	2021-02-25
EP3471780B1 (en)	2020-10-28

Publication	Publication Date	Title
ZA201808538B (en)	2021-04-28	Treatment of amd using aav2 variant with aflibercept
ZA202006746B (en)	2023-03-29	Methods of treatment
ZA201803727B (en)	2019-03-27	Treatment of fibrosis
IL274865A (en)	2020-07-30	Treatment methods with asparaginase
IL258002A (en)	2018-05-31	Cenicriviroc combination therapy for the treatment of fibrosis
IL250960A0 (en)	2017-04-30	Combined treatment of sinecriviroc for the treatment of leprosy
IL247515A0 (en)	2016-11-30	Snekribirock for the treatment of leprosy
ZA201705847B (en)	2020-03-25	Treatment of pain
IL253617A0 (en)	2017-09-28	Snekribirock for the treatment of leprosy
GB201614415D0 (en)	2016-10-05	Enzymes for the treatment of human enterometabolic dysfunction
SG11202005850VA (en)	2020-07-29	Methods of treatment of hypertrigl yceridemia
ZA201608406B (en)	2019-03-27	Enzyme treatment composition
ZA201608775B (en)	2018-05-30	Hair treatment composition
GB201512139D0 (en)	2015-08-19	Methods of treatment
GB201407806D0 (en)	2014-06-18	Treatment of fibrosis
ZA201608404B (en)	2019-05-29	Enzyme treatment composition
GB201607972D0 (en)	2016-06-22	Hair treatment composition
GB201418268D0 (en)	2014-11-26	Composition & methods of treatment